In this episode of Make Medicines Affordable, Tracy Swan speaks with Maureen Mung’asia, Clinical Team Lead at the Centre of International Health, Education and Biosecurity (CIHEB) in Nairobi, Kenya, about the early rollout of long-acting injectable HIV prevention with lenacapavir. Kenya has recently introduced the programme, but access remains limited, with only a small number of facilities offering the injections and 21,000 doses initially available nationwide.

In this episode, Maureen explains how this is shaping demand, access challenges, and geographic inequities, and shares her expariences with administering lenacapaivr. The conversation explores how healthcare providers are adapting to delivering a new injectable prevention method, from staff training and integration into existing HIV services to addressing patient concerns about injections, side effects, and stigma.

Maureen reflects on strong demand from key populations, the importance of choice in HIV prevention, and the realities of supply uncertainty. Despite challenges, she describes lenacapavir as a “game changer” that could significantly improve adherence and reduce new HIV infections if access expands.